Literature DB >> 33989889

Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer.

Dana M van der Heide1, Kiran K Turaga2, Carlos H F Chan1, Scott K Sherman3.   

Abstract

BACKGROUND: Young adults with metastatic colorectal cancer (mCRC) may have higher rates of deficient mismatch repair (dMMR) than older patients. This study sought to assess patterns of MMR-testing and survival among young adult mCRC patients in the National Cancer Database (NCDB), hypothesizing that dMMR correlates with worse survival than in MMR-proficient (pMMR) patients.
METHODS: Stage-IV colorectal cancers were identified in NCDB (2010-2016). Demographic and clinical features were compared between younger (age ≤ 30) and older mCRC patients and tested for association with overall survival. Stage-IV disease without other recorded metastatic sites defined peritoneal metastasis (PM). Fisher-exact tests compared proportions and Cox models tested association with overall survival.
RESULTS: Of 124,587 stage-IV colorectal cancers, 1,123 (0.9%) were in young patients. Young patients were more likely to have mucinous histology, high-grade, rectal primaries, and isolated peritoneal metastases (P < 0.001). Younger patients more often had MMR-testing (29.1 versus 16.6%), with dMMR found at similar rates in young and older patients (21.7 versus 17.1% of those tested, P= 0.4). Despite higher rates of adverse prognostic features, younger patients had better survival (median 20.7 versus 14.8 months, P < 0.001). In MMR-tested patients, dMMR correlated with higher mortality risk compared to pMMR (median 16.6 months versus 25.5 months, P = 0.01). On multivariable analysis, grade and MMR-status remained independently associated with survival.
CONCLUSIONS: Median survival was worse with dMMR by 8.9 months compared to pMMR in young adults with mCRC. Despite higher rates of familial syndromes in young patients and recommendations for universal MMR-testing, over 70% of young mCRC patients had no MMR-status recorded.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Colon Cancer; Genetic Testing; Mismatch Repair; Outcomes; Peritoneal Metastases; Survival; Tumors

Mesh:

Substances:

Year:  2021        PMID: 33989889      PMCID: PMC8338754          DOI: 10.1016/j.jss.2021.03.040

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.417


  31 in total

1.  Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

Authors:  Thierry André; Kai-Keen Shiu; Tae Won Kim; Benny Vittrup Jensen; Lars Henrik Jensen; Cornelis Punt; Denis Smith; Rocio Garcia-Carbonero; Manuel Benavides; Peter Gibbs; Christelle de la Fouchardiere; Fernando Rivera; Elena Elez; Johanna Bendell; Dung T Le; Takayuki Yoshino; Eric Van Cutsem; Ping Yang; Mohammed Z H Farooqui; Patricia Marinello; Luis A Diaz
Journal:  N Engl J Med       Date:  2020-12-03       Impact factor: 91.245

2.  Evaluating the Combination of Microsatellite Instability and Mutation in BRAF as Prognostic Factors for Patients With Colorectal Cancer.

Authors:  Frank A Sinicrope
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-30       Impact factor: 11.382

Review 3.  Rising incidence of early-onset colorectal cancer in Australia over two decades: report and review.

Authors:  Joanne P Young; Aung Ko Win; Christophe Rosty; Ingrid Flight; David Roder; Graeme P Young; Oliver Frank; Graeme K Suthers; Peter J Hewett; Andrew Ruszkiewicz; Ehud Hauben; Barbara-Ann Adelstein; Susan Parry; Amanda Townsend; Jennifer E Hardingham; Timothy J Price
Journal:  J Gastroenterol Hepatol       Date:  2015-01       Impact factor: 4.029

4.  Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.

Authors:  Ben Tran; Scott Kopetz; Jeanne Tie; Peter Gibbs; Zhi-Qin Jiang; Christopher H Lieu; Atin Agarwal; Dipen M Maru; Oliver Sieber; Jayesh Desai
Journal:  Cancer       Date:  2011-03-31       Impact factor: 6.860

5.  Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors.

Authors:  Alberto Puccini; Heinz-Josef Lenz; John L Marshall; David Arguello; Derek Raghavan; W Michael Korn; Benjamin A Weinberg; Kelsey Poorman; Arielle L Heeke; Philip A Philip; Anthony F Shields; Richard M Goldberg; Mohamed E Salem
Journal:  Oncologist       Date:  2018-07-17

6.  Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives.

Authors: 
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

7.  Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.

Authors:  Sabine Venderbosch; Iris D Nagtegaal; Tim S Maughan; Christopher G Smith; Jeremy P Cheadle; David Fisher; Richard Kaplan; Philip Quirke; Matthew T Seymour; Susan D Richman; Gerrit A Meijer; Bauke Ylstra; Danielle A M Heideman; Anton F J de Haan; Cornelis J A Punt; Miriam Koopman
Journal:  Clin Cancer Res       Date:  2014-08-19       Impact factor: 12.531

8.  Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.

Authors:  Dung T Le; Tae Won Kim; Eric Van Cutsem; Ravit Geva; Dirk Jäger; Hiroki Hara; Matthew Burge; Bert O'Neil; Petr Kavan; Takayuki Yoshino; Rosine Guimbaud; Hiroya Taniguchi; Elena Elez; Salah-Eddin Al-Batran; Patrick M Boland; Todd Crocenzi; Chloe E Atreya; Yi Cui; Tong Dai; Patricia Marinello; Luis A Diaz; Thierry André
Journal:  J Clin Oncol       Date:  2019-11-14       Impact factor: 44.544

9.  Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.

Authors:  G Emerens Wensink; Marloes A G Elferink; Anne M May; Linda Mol; Patricia A H Hamers; Sandra D Bakker; Geert-Jan Creemers; Jan Willem B de Groot; Gerty J de Klerk; Brigitte C M Haberkorn; Annebeth W Haringhuizen; Ronald Hoekstra; J Cornelis B Hunting; Emile D Kerver; Danielle Mathijssen-van Stein; Marco B Polée; Johannes F M Pruijt; Patricia Quarles van Ufford-Mannesse; Sandra Radema; Ronald C Rietbroek; Lieke H J Simkens; Bea C Tanis; Daan Ten Bokkel Huinink; Manuel L R Tjin-A-Ton; Cathrien S Tromp-van Driel; Monique M Troost; Agnes J van de Wouw; Franchette W P J van den Berkmortel; Anke J M van der Pas; Ankie M T van der Velden; Marjan A van Dijk; Joyce M van Dodewaard-de Jong; Edith B van Druten; Theo van Voorthuizen; Gerrit Jan Veldhuis; Henk M W Verheul; Hanneke J H M J Vestjens; Jeroen Vincent; Onno W Kranenburg; Cornelis J A Punt; Geraldine R Vink; Jeanine M L Roodhart; Miriam Koopman
Journal:  Br J Cancer       Date:  2020-10-13       Impact factor: 7.640

Review 10.  Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer.

Authors:  Cong-Min Zhang; Jin-Feng Lv; Liang Gong; Lin-Yu Yu; Xiao-Ping Chen; Hong-Hao Zhou; Lan Fan
Journal:  Int J Environ Res Public Health       Date:  2016-09-08       Impact factor: 3.390

View more
  2 in total

1.  Development of novel models for predicting mismatch repair protein deficiency and relevant disease-free survival in colorectal cancer patients.

Authors:  Yixin Xu; Yuzhe Li; Ziyan Zhu; Jing Yang; Yulin Tan; Yibo Wang; Xuezhong Xu
Journal:  Int J Colorectal Dis       Date:  2022-04-28       Impact factor: 2.571

Review 2.  Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline.

Authors:  Irene S Yu; Francine Aubin; Rachel Goodwin; Jonathan M Loree; Cheryl Mather; Brandon S Sheffield; Stephanie Snow; Sharlene Gill
Journal:  Ther Adv Med Oncol       Date:  2022-07-20       Impact factor: 5.485

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.